References:
- Libby P. Mechanisms of acute coronary syndromes and their implications
for therapy. N Engl J Med. 2013 May 23;368(21):2004-13. doi:
10.1056/NEJMra1216063. PMID: 23697515.
- Yakushkin VV, Zyuryaev IT, Khaspekova SG, Sirotkina OV, Ruda MY,
Mazurov AV. Glycoprotein IIb-IIIa content and platelet aggregation in
healthy volunteers and patients with acute coronary syndrome.
Platelets. 2011;22(4):243-51. doi: 10.3109/09537104.2010.547959. Epub
2011 Feb 17. PMID: 21329420.
- Bansal AB, Sattar Y, Jamil RT. Eptifibatide. 2022 Jan 25. In:
StatPearls [Internet]. Treasure Island (FL): StatPearls
Publishing; 2022 Jan–. PMID: 31082110.
- Aljundi A, Rahhal A, Dabdoob W. Acute Stent Thrombosis Associated with
Eptifibatide-Induced Profound Thrombocytopenia. Case Rep Cardiol. 2020
Jun 9;2020:8386709. doi: 10.1155/2020/8386709. PMID: 32566320; PMCID:
PMC7303759.Inhibition of platelet glycoprotein IIb/IIIa with
eptifibatide in patients with acute coronary syndromes. The PURSUIT
trial investigators. Platelet glycoprotein IIb/IIIa in unstable
angina: receptor suppression using integrilin therapy. N Engl J Med.
1998;339:436–443.
- Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in
patients with acute coronary syndromes. The PURSUIT trial
investigators. Platelet glycoprotein IIb/IIIa in unstable angina:
receptor suppression using integrilin therapy. N Engl J Med.
1998;339:436–443.
- O’Shea JC, Hafley GE, Greenberg S, et al; ESPRIT Investigators
(Enhanced Suppression of the Platelet IIb/IIIa Receptor with
Integrilin Therapy trial). Platelet glycoprotein IIb/IIIa integrin
blockade with eptifibatide in coronary stent intervention: the ESPRIT
trial: a randomized controlled trial. JAMA. 2001;285:2468–2473.
- Randomised placebo-controlled trial of effect of eptifibatide on
complications of percutaneous coronary intervention: IMPACT-II.
Integrilin to minimise platelet aggregation and coronary
thrombosis-II. Lancet. 1997;349:1422–1428.
- Refaat, M., Smith, A. J. C., & Edmundowicz, D.
(2007). Eptifibatide-induced thrombocytopenia. Journal of
Thrombosis and Thrombolysis, 25(2),
204–206. doi:10.1007/s11239-007-0166-x
- Pothineni NV, Watts TE, Ding Z, Dai Y, Deshmukh AJ.
Eptifibatide-Induced Thrombocytopenia–When Inhibitor Turns Killer.
Am J Ther. 2016 Jan-Feb;23(1):e298-9. doi:
10.1097/01.mjt.0000438283.01797.1a. PMID: 24368608.
- Coons JC, Barcelona RA, Freedy T, Hagerty MF. Eptifibatide-associated
acute, profound thrombocytopenia. Ann Pharmacother. 2005
Feb;39(2):368-72. doi: 10.1345/aph.1E244. Epub 2005 Jan 11. PMID:
15644467.
- Boettcher BT, Olund TJ, Pagel PS. Acute Severe Thrombocytopenia
Occurring After Administration of Eptifibatide Postpones Emergent
Coronary Artery Surgery. Anesth Pain Med. 2016 Jun 21;6(4):e37575.
doi: 10.5812/aapm.37575. PMID: 27843778; PMCID: PMC5099974.
- Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and
prevention of heparin-induced thrombocytopenia: American College of
Chest Physicians Evidence-Based Clinical Practice Guidelines (8th
Edition). Chest. 2008 Jun;133(6 Suppl):340S-380S. doi:
10.1378/chest.08-0677. Erratum in: Chest. 2011 May;139(5):1261. Dosage
error in article text. PMID: 18574270.